Highlights From Pharmaceutical Strategic Alliances: The Importance Of Emerging Markets
Executive Summary
One of the key take-aways from a wide-ranging hour-long panel discussion on emerging markets at Elsevier Business Intelligence's 20th Pharmaceutical Strategic Alliances meeting was the notion that drugmakers cannot implement a one-size-fits-all strategy when building a presence in important new markets. Participating in the forum were Mervyn Turner, PhD, chief strategy officer of Merck , Jean-Michel Halfon, president and general manager of Pfizer's emerging markets business unit, and Robin Arnold, a consultant with IMS Health.
You may also be interested in...
Key Considerations For Launching Pharmaceutical Products In Emerging Markets
In light of growing revenue opportunities from emerging markets, we highlight tactics and successful examples for companies to leverage in overcoming challenges of low disease awareness and changing practice patterns.
Key Considerations For Launching Pharmaceutical Products In Emerging Markets
In light of growing revenue opportunities from emerging markets, we highlight tactics and successful examples for companies to leverage in overcoming challenges of low disease awareness and changing practice patterns.
Pfizer Shake Up Continues With Key Exits From Emerging Markets
In the wake of CEO Jeff Kindler's abrupt departure earlier this week, Pfizer has announced two key departures from its emerging markets team, suggesting greater changes may be on the way at the world's largest drug maker